
|Articles|January 12, 2021
Clearside Biomedical's axitinib injectable suspension phase 1/2a trial enrolls first patients
Author(s)OT Staff Reports
Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement






















